GDTC
Income statement / Annual
Last year (2024), CytoMed Therapeutics Limited's total revenue was $52.01 K,
a decrease of 82.10% from the previous year.
In 2024, CytoMed Therapeutics Limited's net income was -$1.88 M.
See CytoMed Therapeutics Limited,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$52.01 K |
$290.56 K |
$270.34 K |
$84.18 K |
$44.92 K |
$0.00 |
| Cost of Revenue |
$567.82 K
|
$77.47 K
|
$6.48 K
|
$2.59 K
|
$3.50 K
|
$0.00
|
| Gross Profit |
-$515.82 K
|
$213.09 K
|
$263.86 K
|
$81.59 K
|
$41.43 K
|
$0.00
|
| Gross Profit Ratio |
-9.92
|
0.73
|
0.98
|
0.97
|
0.92
|
0
|
| Research and Development Expenses |
$1.43 M
|
$1.20 M
|
$1.13 M
|
$806.45 K
|
$784.20 K
|
$323.98 K
|
| General & Administrative Expenses |
$0.00
|
$344.25 K
|
$443.29 K
|
$433.47 K
|
$112.32 K
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$25.24 K
|
$0.00
|
$1.83 K
|
$4.67 K
|
$0.00
|
| Selling, General & Administrative Expenses |
$675.21 K
|
$1.93 M
|
$443.29 K
|
$435.31 K
|
$116.99 K
|
$29.72 K
|
| Other Expenses |
$7.70 K
|
$0.00
|
-$195.32 K
|
$36.13 K
|
$47.81 K
|
$0.00
|
| Operating Expenses |
$2.11 M
|
$3.12 M
|
$1.38 M
|
$1.28 M
|
$949.00 K
|
$451.04 K
|
| Cost And Expenses |
$3.20 M
|
$3.20 M
|
$1.38 M
|
$1.28 M
|
$949.00 K
|
$451.04 K
|
| Interest Income |
$237.70 K
|
$38.73 K
|
$1.52 K
|
$2.51 K
|
$79.71 K
|
$20.06 K
|
| Interest Expense |
$15.20 K
|
$0.00
|
$90.77 K
|
$87.58 K
|
$79.71 K
|
$0.00
|
| Depreciation & Amortization |
$91.59 K
|
$77.47 K
|
$291.84 K
|
$243.92 K
|
$220.99 K
|
$97.23 K
|
| EBITDA |
-$1.79 M |
-$2.94 M |
-$1.11 M |
-$1.19 M |
-$728.02 K |
-$349.62 K |
| EBITDA Ratio |
-34.43
|
-10.11
|
-4.11
|
-14.12
|
-16.21
|
0
|
| Operating Income Ratio |
-50.5
|
-10.02
|
-5.19
|
-17.02
|
-21.12
|
0
|
| Total Other Income/Expenses Net |
$728.83 K
|
-$219.50 K
|
-$922.48 K
|
-$320.96 K
|
-$513.22 K
|
-$19.10 K
|
| Income Before Tax |
-$1.90 M
|
-$3.13 M
|
-$2.33 M
|
-$1.53 M
|
-$1.47 M
|
-$465.95 K
|
| Income Before Tax Ratio |
-36.48
|
-10.78
|
-8.6
|
-18.22
|
-32.66
|
0
|
| Income Tax Expense |
$0.00
|
$373.69
|
$1.22 K
|
-$53.43 K
|
$84.71 K
|
$0.00
|
| Net Income |
-$1.88 M
|
-$3.13 M
|
-$2.40 M
|
-$1.53 M
|
-$1.47 M
|
-$465.95 K
|
| Net Income Ratio |
-36.21
|
-10.78
|
-8.87
|
-18.22
|
-32.66
|
0
|
| EPS |
-0.16 |
-0.29 |
-0.30457 |
-0.22183 |
-0.24929 |
-0.08102097 |
| EPS Diluted |
-0.16 |
-0.29 |
-0.30457 |
-0.22183 |
-0.24929 |
-0.08102097 |
| Weighted Average Shares Out |
$11.54 M
|
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Weighted Average Shares Out Diluted |
$11.54 M
|
$10.63 M
|
$7.92 M
|
$6.93 M
|
$5.90 M
|
$5.55 M
|
| Link |
|
|
|
|
|
|
